Assessment of the genetic effects of polymorphisms in the osteoprotegerin gene, TNFRSF11B, on serum osteoprotegerin levels and carotid plaque vulnerability

Stroke

Volumn 42, Issue 11, 2011, Pages 3022-3028

  Straface, Giuseppe ^a   Biscetti, Federico ^b,c   Pitocco, Dario ^b   Bertoletti, Giovanni ^d   Misuraca, Maria ^d   Vincenzoni, Claudio ^b   Snider, Francesco ^b   Arena, Vincenzo ^c   Stigliano, Egidio ^c   Angelini, Flavia ^c   Iuliano, Luigi ^a   Boccia, Stefania ^c,e   De Waure, Chiara ^c   Giacchi, Francesco ^b   Ghirlanda, Giovanni ^b,c   Flex, Andrea ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d St M Goretti Hospital   (Italy)

^e IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

carotid artery; carotid atherosclerosis; gene polymorphisms; osteoprotegerin; stable and unstable plaques

Indexed keywords

OSTEOPROTEGERIN;

AGED; ARTICLE; CAROTID ATHEROSCLEROSIS; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RESTRICTION MAPPING; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CAROTID STENOSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; MALE; MIDDLE AGED; OSTEOPROTEGERIN; PLAQUE, ATHEROSCLEROTIC; POLYMORPHISM, GENETIC;

EID: 80054996054     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.111.619288     Document Type: Article

References (37)

1. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W Jr, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerotic. A report from the Committee on Vascular Lesions of Council on Atherosclerosis, American Heart Association. Circulation. 1995;92:1355-1374.
2. Virchow R. Cellular Pathology: As Based Upon Physiological and Pathological Histology. New York, NY: Dover, 1863.
3. Demer LL, Watson KE, Boström K. Mechanism of calcification in atherosclerosis. Trends Cardiovasc Med. 1994;4:45-49. (Pubitemid 24105448)
4. Wexler L, Crouse J, Detrano R, Fuster V, Maddahi J, Rumberger J, et al. Coronary artery calcification: pathophysiology, epidemiology, imaging methods, and clinical implications. A statement for health professionals from the American Health Association. Circulation. 1996;94:1175-1192. (Pubitemid 26292883)
5. Fitzpatrick LA, Severson A, Edwards WD, Ingram RT. Diffuse calcification in human coronary arteries. J Clin Invest. 1994;94:1597-1604.
6. Boström K, Watson KE, Horn S, Wortham C, Herman IM, Demer LL. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest. 1993;91:1800-1809. (Pubitemid 23127387)
7. Ziegler S, Kudlacek S, Luger A, Minar E. Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. Atherosclerosis. 2005;182:175-180. (Pubitemid 41188384)
8. Ueland T, Yndestad A, Øie E, Florholmen G, Halvorsen B, Frøland SS, et al. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation. 2005;111:2461-2468. (Pubitemid 40696134)
9. Golledge J, McCann M, Mangan S, Lam A, Karan M. Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke. 2004;35:1636-1641. (Pubitemid 38823639)
10. Sandberg WJ, Yndestad A, Øie E, Smith C, Ueland T, Ovchinnikova O, Robertson AK, et al. Enhanced T cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Arterioscler Thromb Vasc Biol. 2006;26:857-863. (Pubitemid 43732163)
11. Kadoglou NP, Gerasimidis T, Golemati S, Kapelouzou A, Karayannacos PE, Liapis CD. The relationship between serum levels of vascular calcification inhibitors and carotid plaque vulnerability. J Vasc Surg. 2008; 47:55-62.
12. Crisafulli A, Micari A, Altavilla D, Saporito F, Sardella A, Passaniti M, et al. Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction. Clin Sci (Lond). 2005;109: 389-395. (Pubitemid 41445246)
13. Styrkarsdottir U, Halldorsson BV, Gretarsdottir S, Gudbjartsson DF, Walters GB, Ingvarsson T, et al. Multiple genetic loci for bone mineral density and fractures. N Engl J Med. 2008;358:2355-2365. (Pubitemid 351749159)
14. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res. 2004;95: 1046-1057. (Pubitemid 39557891)
15. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis, N Engl J Med. 1991;325: 445-453.
16. Moore WS, Barnett HJ, Beebe HG, Bernstein EF, Brener BJ, Brott T, et al. Guidelines for carotid endarterectomy: A multidisciplinary consensus statement from the ad hoc committee, American Heart Association, Stroke. 1995;26:188-201.
17. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid artery stenosis, JAMA. 1995;273:1421-1428.
18. Soufi M, Schoppet M, Sattler AM, Herzum M, Maisch B, Hofbauer LC, et al. Osteoprotegerin gene polymorphisms in men with coronary artery disease. J Clin Endocrinol Metab. 2004;89:3764-3768. (Pubitemid 39071469)
19. Pitocco D, Zelano G, Gioffrè G, Di Stasio E, Zaccardi F, Martini F, et al. Association between osteoprotegerin G1181C and T245G polymorphisms and diabetic charcot neuroarthropathy: A case-control study. Diabetes Care. 2009;32:1694-1697.
20. Terwilliger J, Ott J Handbook of Human Genetic Linkage. John Hopkins University Press, Baltimore 1994.
21. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001;68: 978-989. (Pubitemid 32289743)
22. J. Attia, A. Thakkinstian C. D'Este. Meta-analyses of molecular association studies: methodologic lessons for genetic epidemiology. J Clin Epidemiol. 2003;56:297-303. (Pubitemid 36593307)
23. Jono S, Ikari Y, Shioi A, Mori K, Miki T, Hara K, et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation. 2002;106:1192-1194. (Pubitemid 34988634)
24. Schoppet M, Sattler AM, Schaefer JR, Herzum M, Maisch B, Hofbauer LC. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab. 2003;88:1024-1028. (Pubitemid 36337751)
25. Ueland T, Jemtland R, Godang K, Kjekshus J, Hognestad A, Omland T, et al. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol. 2004;44:1970-1976. (Pubitemid 39473280)
26. Vik A, Brodin E, Borvik T, Sveinbjornsson B, Hansen JB. Serum osteoprotegerin in young survivors of myocardial infarction. Thromb Haemost. 2006;95:881-885.
27. Lieb W, Gona P, Larson MG, Massaro JM, Lipinska I, Keaney JF Jr, et al. Biomarkers of the Osteoprotegerin Pathway. Clinical Correlates, Subclinical Disease, Incident Cardiovascular Disease, and Mortality. Arterioscler Thromb Vasc Biol. 2010;30:1849 -1854.
28. Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, Mayr A, et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation. 2004;109:2175-2180. (Pubitemid 38625393)
29. Semb AG, Ueland T, Aukrust P, Wareham NJ, Luben R, Gullestad L, et al. Osteoprotegerin and soluble receptor activator of nuclear factorkappaB ligand and risk for coronary events: A nested case-control approach in the prospective EPIC-Norfolk population study 1993-2003. Arterioscler Thromb Vasc Biol. 2009;29:975-980.
30. Browner WS, Lui L-Y, Cummings SR. Associations of Serum Osteoprotegerin Levels with Diabetes, Stroke, Bone Density, Fractures, and Mortality in Elderly Women. J Clin Endocrinol Metab. 2001;86:631-637. (Pubitemid 32207471)
31. Libby P. Current Concepts of the Pathogenesis of the Acute Coronary Syndromes. Circulation. 2001;104:365-372. (Pubitemid 32666962)
32. Abedin M, Omland T, Ueland T, Khera A, Aukrust P, Murphy SA, et al. Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). Am J Cardiol. 2007;99:513-518. (Pubitemid 46215559)
33. Wittrant Y, Couillaud S, Theoleyre S, Dunstan C, Heymann D, Redini F. Osteoprotegerin differentially regulates protease expression in osteoclast cultures. Biochem Biophys Res Commun. 2002;293:38-44. (Pubitemid 34694167)
34. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem. 1998;273:14363-14367. (Pubitemid 28319153)
35. Shin JY, Shin YG, Chung CH. Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 diabetes. Diabetes Care. 2006;29:1664-1646.
36. Xiang GD, Xu L, Zhao LS, Yue L, Hou J. The relationship between plasma osteoprotegerin and endothelium-dependent arterial dilation in type 2 diabetes. Diabetes. 2006;55:2126-2131. (Pubitemid 44509988)
37. Golledge J, Leicht AS, Crowther RG, Glanville S, Clancy P, Sangla KS, et al. Determinants of endothelial function in a cohort of patients with peripheral artery disease. Cardiology. 2008;111:51-56.